TABLE 1.
Clinicopathological characteristics of all patients separated by serum concentration of HER2.
| Clinicopathogical features | Low concentration group ≤ 11.6 ng/mL N = 151 | High concentration group > 1.6 ng/mL N = 62 | P value |
| Gender (male/female) | 101:50 | 52:10 | 0.012* |
| Age (years) | 57.4 ± 11.3 | 57.7 ± 9.2 | 0.747 |
| Tumor location (U/M/L/UML) | 44:14:90:3 | 24:5:33:0 | 0.512 |
| Tumor size (cm) | 5.1 ± 2.7 | 4.1 ± 2.1 | 0.021* |
| Differentiation (well/poorly) | 15:136 | 14:48 | 0.014* |
| Pathological expression level of HER2 (low/high) | 126:25 | 47:15 | 0.195 |
| T stage | 0.008* | ||
| T1 | 23 (15.23%) | 15 (24.19%) | |
| T2 | 26 (17.22%) | 12 (19.35%) | |
| T3 | 42 (27.81%) | 25 (40.32%) | |
| T4 | 60 (39.74%) | 10 (16.13%) | |
| N stage | 0.165 | ||
| N0 | 44 (29.14%) | 26 (41.94%) | |
| N1 | 20 (13.25%) | 10 (16.13%) | |
| N2 | 29 (19.21%) | 11 (17.74%) | |
| N3 | 58 (38.41%) | 15 (24.19%) | |
| M stage | 0.947 | ||
| M0 | 131 (86.75%) | 54 (87.10%) | |
| M1 | 20 (13.25%) | 8 (12.90%) | |
| TNM stage | 0.118 | ||
| I | 31 (20.53%) | 22 (35.48%) | |
| II | 34 (22.52%) | 13 (20.97%) | |
| III | 66 (43.71%) | 19 (30.65%) | |
| IV | 20 (13.25%) | 8 (12.90%) |
*P < 0.05, statistical significance.